Dextran '70' 6% / Sodium chloride 0.9% infusion 500ml bags
Pharmaceutical compound
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Dextran 70 + Sodium chloride
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Dextran 70 + Sodium chloride on the MHRA register
Dextran '70' 6% in sodium chloride 0.9% solution for injection 500ml bags
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing all 21 studies.
Reviews & meta-analyses: 1 · 1981–2026
Showing all 21 studies, sorted by most relevant.
K. Mattox, K. Mattox, P. Maningas, et al.
Annals of surgery, 1991
- Fluid Therapy
- Dextrans
- Hypotension
M. Vassar, R. Fischer, Paul E. O'Brien, et al.
Archives of surgery, 1993
- Resuscitation
- Ringer's Solution
- Blood Pressure
M. Vassar, C. A. Perry, W. L. Gannaway, et al.
Archives of surgery, 1991
- Aircraft
- Emergency Medical Services
- Ringer's Lactate
George C. Kramer, P. Perron, D. Lindsey, et al.
Surgery, 1986
M. Vassar, C. A. Perry, J. Holcroft
Archives of surgery, 1990
Kotenkova E, Kotov A, Nikitin M
2025
Global concerns about environmental pollution, poor waste management, and the rise in antimicrobial resistance due to uncontrolled antibiotic use have driven researchers to seek alternative, multifaceted solutions. Plants, animals, microorganisms, and their processing wastes serve as valuable sources of natural biopolymers and bioactive compounds. Through nanotechnology, these can be assembled into formulations with enhanced antimicrobial properties, high safety, and low toxicity. This review explores polysaccharides, including chitosan, alginate, starch, pectin, cellulose, hemicellulose, gums, carrageenan, dextran, pullulan, and hyaluronic acid, used in nanotechnology, highlighting their advantages and limitations as nanocarriers. Addressing the global urgency for alternative antimicrobials, we examined natural compounds derived from plants, microorganisms, and animals, such as phytochemicals, bacteriocins, animal antimicrobial peptides, and proteins. Focusing on their protection and retained activity, this review discusses polysaccharide-based nanoformulations with natural antimicrobials, including nanoparticles, nanoemulsions, nanocapsules, nanoplexes, and nanogels. Special emphasis is placed on strategies and formulations for the encapsulation, entrapment, and conjugation of natural compounds using polysaccharides as protective carriers and delivery systems, including a brief discussion on their future applications, prospects, and challenges in scaling up.
Abstract licence: CC BY
Cooper A, Vijayananda V, Pazzi J, et al.
2025
- Polymers
- Nanostructures
- Unilamellar Liposomes
Thin film hydration methods are widely used to assemble giant unilamellar vesicles (GUVs), but their efficiency drops sharply in solutions of physiological ionic strength due to enhanced adhesion between stacked lipid bilayers, which suppresses bud and foam-like mesophase formation. Here, polymer-coated nanocellulose paper (PCP) is introduced as a nanostructured substrate that overcomes this limitation. Hydration of lipid films on PCP, termed PCP-assisted hydration, achieves high GUV yields across a broad temperature range (4 °C-45 °C) using diverse soluble polymers, including ultralow-gelling agarose, hyaluronic acid, dextran, carrageenan, and polylysine. The nanoscale curvature of the cellulose fibers and the osmotic pressure generated by polymer dissolution act synergistically to promote membrane budding even under physiological salt conditions. The approach is scalable-supporting GUV production from millimeter-sized pieces to large-format sheets-and biocompatible, enabling encapsulation of complex biochemical systems such as cell-free expression mixtures and actin-fascin assemblies. PCP-assisted hydration thus provides a robust, versatile, and high-yielding platform for generating functional GUVs under physiological conditions.
Abstract licence: CC BY
Solé-Domènech S, Singh PK, Funes L, et al.
2025
- Fluorescent Dyes
- Lysosomes
- Macrophages
Active endolysosomal pH regulation is essential for optimal enzymatic activity. To measure acidification, pH sensors can be delivered to acidic compartments using labeled dextran polymers or proteins. However, commercial probes have limited sensitivity in the acidic endolysosomal range or their fluorescence undergoes degradation. Herein, we introduce the new pH-sensitive probe ApHID, a green-emitting sensor with optimal dynamic range matching the acidity of endosomes and lysosomes. Acid pH indicator dye (ApHID) has a pKa near 5, increasing brightness with acidity, and withstands oxidation and photobleaching. We used ApHID dextrans to measure endolysosomal pH in macrophages and compared it to other commercially available sensors. ApHID reported pH accurately and stably over time in cell culture and was sensitive to subtle variations in organelle acidification in real time. Overall, ApHID circumvents limitations of currently available commercial probes and can provide utility in demanding applications such as intravital imaging of tissues.
Abstract licence: CC BY
Wang Y, Li K, Chen W, et al.
2026
- Chlorides
- Lysosomes
- Membrane Glycoproteins
Neurodegenerative diseases, which pose significant challenges for effective treatment, often involve risk variants of lysosomal gene products that disrupt lysosomal function, leading to the accumulation of indigestible materials and damage to brain cells. The lysosome is a degradative organelle and a signaling hub that senses nutrient availability. How lysosomal dysfunction contributes to neurodegenerative diseases is an important open question. In this study, we identified CLN3 (ceroid lipofuscinosis, neuronal 3), an endolysosomal protein that is linked to Batten disease, as an evolutionarily conserved protein that facilitates lysosomal chloride efflux. Additionally, we report that a natural compound with anti-inflammatory properties-the curcumin analog C1, which is a TFEB (transcription factor EB) activator-could enhance CLN3 activity and improve lysosomal function. These findings provide new insight into the role of CLN3 in lysosomal ion homeostasis and raise the possibility that modulation of the TFEB-CLN3 signaling axis may hold therapeutic potential for lysosomal storage disorders.
Abstract licence: CC BY
J. Heyser, M. Nabors
Plant physiology, 1981
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q28163637), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.